Analysis
Picked for the recovery-and-tendon shelf when budget matters. The full TB-4 protein has small-trial data; the synthetic fragment that ships as TB-500 does not.
TB-500 is the budget pick for tendon and connective-tissue work because the underlying biology, G-actin sequestration, cell migration, modulation of inflammatory cytokines, is well-established cell biology, not a marketing back-fit. The complication is that almost every online source treats 'TB-500' and 'thymosin beta-4' as interchangeable, and they are not. TB-4 is the full 43-residue protein with published Phase 1 and Phase 2 data in corneal injury and dermal wound healing. TB-500 is a synthetic short-fragment derivative that ships through research-peptide channels with very little of its own clinical literature. We score the file under TB-500 the marketed compound, not TB-4 the protein, which is why the human-data column reads 3.2 and not 6.5. WADA has prohibited TB-500 by name since 2014 and athletes have been sanctioned, which v1.2 captures in the regulatory posture column.
Top vier auf jeder Dimension.
Höher ist besser. Zahlen sind tabellarisch, die Methodik steht auf der Methodik-Seite, und ja — Anbieter-Verlässlichkeit zählt, weil das Fälschungsrisiko real ist.
Vor- und Nachteile
| WAS FUNKTIONIERT | WAS NICHT FUNKTIONIERT |
|---|---|
| Actin-sequestering mechanism is textbook cell biology, the science is not invented. | The marketed 'TB-500' is a synthetic fragment; trial data on TB-4 does not transfer cleanly. |
| Lower price point than BPC-157 in research-channel supply, hence the budget pick. | WADA explicitly prohibits TB-500, competitive athletes have been sanctioned. |
| Some Phase 1/2 data exists for the parent thymosin beta-4 in wound and corneal indications. | Counterfeit incidence in research-channel supply higher than BPC-157. |
Alternativen, die wir getestet haben
Drei Substanzen, die im selben Vergleichsset auftauchten.
- #1 · LEITREVIEW6.8BPC-157Body Protection Compound 157
The most-studied research peptide in rodents. Human evidence remains thin and the FDA narrowed its compounding pathway in 2023.
- #3 · HÖCHSTE WERTUNG8.1GHK-CuCopper tripeptide
The cleanest evidence file in the database, peer-reviewed cosmetic and wound work, plus topical formulations available outside the research channel.
Quellen
4 cited- Goldstein et al. 2012, thymosin beta-4 review
- Sosne et al. 2010, thymosin beta-4 corneal wound healing Phase 2, Br J Ophthalmol
- Crockford et al. 2010, thymosin beta-4 dermal wound trial, Ann N Y Acad Sci
- WADA Prohibited List 2026